Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
YES
DIRECT
ALG antibodies bind CD11a on T cells and induce complement-dependent lysis and Fc receptor–mediated clearance (ADCC/phagocytosis), depleting the target-expressing cells.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
YES
DIRECT
ALG antibodies bind T‑cell surface antigens (including LFA‑1/CD18), triggering complement-dependent lysis and Fc-mediated effector functions (ADCC/phagocytosis) that deplete CD18+ cells.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
YES
DIRECT
ALG binds CD45 on T lymphocytes and induces complement-dependent cytolysis and Fc-mediated effector clearance (ADCC/phagocytosis).
Autologous, gene-modified CAR T cells engineered to express an anti-CD30 chimeric antigen receptor and CCR4 to enhance trafficking to the Hodgkin lymphoma microenvironment; CAR engagement of CD30 triggers T-cell activation and cytotoxicity.
Autologous T cells are gene-modified to express an anti‑CD30 chimeric antigen receptor and the chemokine receptor CCR4. CAR binding to CD30 on malignant cells triggers T‑cell activation, cytokine release, proliferation, and targeted cytotoxicity, while CCR4 enhances trafficking to the Hodgkin lymphoma microenvironment via CCL17/CCL22 gradients.
YES
DIRECT
Anti-CD30 CAR T cells bind CD30 on target cells, form an immune synapse, and induce apoptosis via perforin/granzyme release (and Fas–FasL signaling); CCR4 only enhances trafficking.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
NO
INDIRECT
ALG binds multiple T‑cell antigens and depletes T cells via complement-dependent lysis and Fc-mediated clearance; it does not specifically target HLA‑DR, so HLA‑DR–expressing cells are not directly killed.